Results 111 to 120 of about 69,701 (316)

Male Factors Associated With Success Following Assisted Reproduction Technology Among Infertile Couples in Ghana

open access: yesAmerican Journal of Men's Health
Assisted reproductive technologies (ARTs) are increasingly utilized in Ghana, as treatment options for couples with infertility, including male factor infertility.
Issac Kofi Adu   +7 more
doaj   +1 more source

2015 Assisted Reproductive Technology National Summary Report [PDF]

open access: yes
The data for this national report come from the 464 fertility clinics in operation in 2015 that provided and verified data on the outcomes of all ART cycles started in their clinics. Of the 231,936 ART cycles performed in 2015 at these reporting clinics,

core  

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

2012 Assisted Reproductive Technology Report \u2014 Graphs and Charts

open access: yes
Graphs and charts from the 2012 Assisted Reproductive Technology National Summary Report provide an in-depth picture of the type, number, and outcome of ART cycles performed in U.S. fertility clinics.

core  

2013 Assisted Reproductive Technology National Summary Report [PDF]

open access: yes
The data for this national report come from the 467 fertility clinics in operation in 2013 that provided and verified data on the outcomes of all ART cycles started in their clinics. Of the 190,773 ART cycles performed in 2013 at these reporting clinics,

core  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

2016 Assisted Reproductive Technology Report \u2014 Graphs and Charts

open access: yes
Graphs and charts from the 2016 Assisted Reproductive Technology National Summary Report provide an in-depth picture of the type, number, and outcome of ART cycles performed in U.S. fertility clinics.

core  

2017 Assisted Reproductive Technology National Summary Report [PDF]

open access: yes
The data for this national report come from the 448 US fertility clinics in operation in 2017 that provided and verified data on the outcomesof all ART cycles started in their clinics.echnology Fertility Clinic Success Rates Report. Of the 284,385 cycles

core  

Law, biopolitics and reproductive citizenship: the Case of assisted reproduction in Italy

open access: yes, 2013
In 2004, the introduction of a restrictive law on assisted reproduction in Italy sees the privileging of a conservative model of family relations and a misogynist view of society by the political elite.
Hanafin, Patrick, Patrick Hanafin
core   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy